Product Revenue, Net was Crinetics Pharmaceuticals’s largest product and service line in fiscal 2025, bringing in $5.42M of $7.22M (75%).
| Product and Service | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Product Revenue, Net | — | — | $5.42M |
| License | $2.10M | — | $1.80M |
| Collaboration & License Revenue | — | $1.04M | — |
| Total | $2.10M | $1.04M | $7.22M |
Crinetics Pharmaceuticals brought in $7.22M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. Crinetics Pharmaceuticals regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $1.04M. Product Revenue, Net was the largest at $5.42M (75.1%), ahead of License at $1.80M (24.9%).
Crinetics Pharmaceuticals began breaking out Product Revenue, Net in fiscal 2025, when it brought in $5.42M. Crinetics Pharmaceuticals stopped reporting Collaboration & License Revenue as a separate line after fiscal 2024, when it brought in $1.04M.
Loyal was Crinetics Pharmaceuticals’s largest product and service line in fiscal 2023, bringing in $2.10M of $4.00M (53%).
| Product and Service | FY 2023 |
|---|---|
| Loyal | $2.10M |
| Sanwa Kagaku Kenkyusho Co Ltd, Sanwa License | $1.50M |
| Sanwa Kagaku Kenkyusho Co Ltd, Sanwa Clinical Supply Agreement | $400.00K |
| Total | $4.00M |
Crinetics Pharmaceuticals brought in $4.00M from its three product and service lines in fiscal 2023, the year ended December 31, 2023. Loyal was the largest at $2.10M (52.5%), ahead of Sanwa Kagaku Kenkyusho Co Ltd, Sanwa License at $1.50M (37.5%) and Sanwa Kagaku Kenkyusho Co Ltd, Sanwa Clinical Supply Agreement at $400.00K (10.0%).
Crinetics Pharmaceuticals (CRNX) reports its revenue by product and service. In fiscal 2025, Product Revenue, Net was its largest product and service line, bringing in $5.42M (75.1% of the total), followed by License at $1.80M (24.9%).
Product Revenue, Net was Crinetics Pharmaceuticals' largest product and service line in fiscal 2025, bringing in $5.42M, or 75.1% of the $7.22M total across its two product and service lines.
Every figure comes from Crinetics Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Crinetics Pharmaceuticals gives it, and years follow its fiscal calendar.
Crinetics Pharmaceuticals' revenue by product and service goes back to fiscal 2023, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.